UNSPSC 51383307: Nepafenac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0J9L7J6V8C, chemically known as benzeneacetamide, 2-amino-3-benzoyl- but generally known as nepafenac, which bears US NIH Compound Identifier 151075. European Medicines Agency schedules Nepafenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09197MIG.

UNSPSC 51383307 Nepafenac, a Commodity code, nominally refers to a specific anti-inflammatory ophthalmic medication, but recent state and local procurement activity under this code shows little alignment with that narrow scope. The three most recent opportunities soliciting under this code—one from Seminole County, Florida seeking naloxone and drug deactivation systems; one from Texas HHS exploring direct-to-manufacturer prescription programs; and one from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic multi-source pharmaceuticals and OTC products—bear no meaningful relationship to nepafenac specifically. State and local issuing bodies tagging opportunities under this code appear to be using it as a catch-all pharmaceutical or medical-supply category rather than as a targeted code for a single ophthalmic drug product. The mismatch between the code's nominal definition and the actual work being solicited suggests either broad category misclassification at the source or systematic tagging error across multiple jurisdictions.

Recent activity spans county health departments (Seminole County), state health agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states (MMCAP, including Oregon participation). The Texas RFI posted April 3, 2026, and the MMCAP RFP with a March 26, 2026 response date represent the most recent formal solicitations, while the Seminole County IFB60459723LAS, posted June 30, 2026 with a July 26 response deadline, is the newest notice. Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multi-state participation extending the reach westward to Oregon. Given the consistent mismatch between the nepafenac code designation and the pharmaceutical procurement categories actually being solicited, this code appears inactive for its intended commodity and should be monitored primarily as a data-quality signal rather than pursued as a reliable pharmaceutical-procurement channel.